WRB Inhibitors
Chemical inhibitors of WRB can exert their effects through different mechanisms, primarily by disrupting various cellular processes that the protein is involved with. Cyclosporin A, by halting calcineurin activity, can reduce the expression of proteins that are vital for maintaining WRB's function in the endoplasmic reticulum (ER) stress pathway. This is significant as WRB is essential for the insertion of tail-anchored proteins into the ER membrane, a process that can be compromised when ER stress is not properly managed. Similarly, the proteasome inhibitor MG-132 can lead to an accumulation of ubiquitinated proteins; this can overwhelm the ER-associated degradation system where WRB plays a crucial role, potentially hindering its ability to facilitate correct protein trafficking. Thapsigargin and Tunicamycin are other examples that disrupt ER functions by different means-Thapsigargin by inhibiting the SERCA pump leading to calcium dysregulation and Tunicamycin by blocking N-linked glycosylation-both of which can lead to ER stress and thus indirectly affect WRB's role in maintaining protein homeostasis within the ER.
Furthermore, Brefeldin A and DBeQ target protein trafficking and degradation pathways, which are closely linked to WRB's function. Brefeldin A's inhibition of ARF disrupts ER-Golgi transport, which can alter the ER membrane environment and impact the integration of proteins, a process in which WRB is involved. DBeQ's inhibition of the p97/VCP complex, critical for ERAD, can also lead to a dysfunctional protein clearance pathway, indirectly affecting WRB's role in the ER. Eeyarestatin I targets similar pathways by inhibiting ERAD-associated enzymes, leading to protein build-up that can tax the ER's capacity, where WRB functions. Guanabenz, by inhibiting IRE1α, affects the unfolded protein response, a key ER stress pathway, thereby potentially compromising WRB's role in ER homeostasis. Finally, MLN4924's inhibition of the NEDD8-activating enzyme can disrupt protein turnover within the ER, impacting the stability of proteins in a manner that can indirectly influence WRB's activity related to protein insertion into the ER membrane.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, and since calcineurin dephosphorylates proteins leading to the translocation of transcription factors like NFAT into the nucleus, its inhibition can reduce the expression of various proteins. Calcineurin has been shown to impact proteins involved in the endoplasmic reticulum (ER) stress pathway, and since WRB is an ER-resident protein involved in the insertion of tail-anchored proteins into the ER membrane, calcineurin inhibition could disrupt the ER stress response and thus the functional state of WRB. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By impeding the proteasome's function, MG-132 can lead to the accumulation of misfolded or damaged proteins within the cell. WRB is implicated in the trafficking of tail-anchored proteins to the ER; an accumulation of proteins due to proteasome inhibition could overwhelm the protein trafficking machinery, affecting WRB's functional role. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the first step in the synthesis of the lipid-linked oligosaccharide precursor for N-linked glycosylation. WRB, being an ER-located protein, may have a role in or be affected by the glycosylation of newly synthesized proteins. Inhibition of glycosylation could result in ER stress and potentially impact WRB function due to a general disruption in ER homeostasis. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels by preventing calcium re-uptake into the ER. Elevated cytosolic calcium can lead to ER stress and a subsequent unfolded protein response (UPR). As WRB is involved in the ER-associated degradation (ERAD) pathway for the clearance of misfolded proteins from the ER, thapsigargin's effect on ER calcium levels could indirectly inhibit WRB by disrupting ER homeostasis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER-Golgi trafficking by inhibiting the ADP-ribosylation factor (ARF). Since WRB is involved in the integration of tail-anchored proteins into the ER membrane, disruption of ER-Golgi transport could impair the function of WRB by altering the ER membrane environment and its associated protein trafficking processes. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
DBeQ is an ATPase inhibitor of the p97/VCP complex, which is involved in various cellular processes including ERAD. WRB is associated with the Get complex that is involved in the insertion of tail-anchored proteins into the ER, a process that could be coupled with ERAD. Inhibition of p97/VCP by DBeQ can disrupt ERAD and, therefore, could indirectly inhibit the function of WRB in the ER membrane. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I interferes with the ERAD pathway by inhibiting the p97 ATPase and associated deubiquitinating enzymes. This inhibition can lead to the accumulation of misfolded proteins in the ER, which would overwhelm the protein processing capacity and could indirectly impact the function of WRB as it is involved in the insertion of proteins into the ER membrane. | ||||||
Guanabenz acetate | 23256-50-0 | sc-203590 sc-203590A sc-203590B sc-203590C sc-203590D | 100 mg 500 mg 1 g 10 g 25 g | $102.00 $468.00 $832.00 $4162.00 $7283.00 | 2 | |
Guanabenz has been reported to selectively inhibit the ER stress sensor IRE1α's RNase activity, which is part of the UPR. As the UPR is critical for maintaining ER function and WRB is an ER-resident protein, guanabenz's inhibition of IRE1α can impair the UPR and indirectly affect WRB's role in ER homeostasis. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA is a histone deacetylase inhibitor and has been shown to induce ER stress by affecting the acetylation state of proteins. WRB, which functions in the ER, could be indirectly inhibited by SAHA through the induction of ER stress and the possible alteration of acetylation states of proteins within the ER, affecting its role in the ER. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for the neddylation process that regulates the activity of cullin-RING E3 ubiquitin ligases. Disruption of this process can lead to the stabilization of proteins that are normally targeted for degradation. Since WRB is involved in the insertion of tail-anchored proteins into the ER membrane, the inhibition of neddylation by MLN4924 could indirectly affect WRB function by altering the turnover and stability of proteins within the ER, potentially leading to ER stress and impacting ER homeostasis. | ||||||